More work needed on new EMA conflicts of interest policy

Abysmal decisions: Why the EC’s medicinal units shouldn’t be moved to DG Industry

Setting precedents: EMA must get clinical trial data policy right to truly act in public interest

HAI Europe calls on EMA's Management Board to stand for data transparency

BMJ statins debate about scientific independence, not rigour

World Health Assembly 67: HAI intervention on the WHO's framework of engagement with non-state actors

Enhancing accountability in the medicines market: The Medicines Transparency Alliance

Regulation critical to clinical trials data transparency in Europe


True clinical trials transparency? Not quite, EFPIA.


Statement on conflicts of interest delivered at WHA on behalf of HAI, Berne Declaration, KEI, TWN, PHM, IBFAN

Conflicts of Interest and the Future of Financing for WHO.

Foundations: Conlicts of interests and Democracy issues

European drug regulator challenged over revolving door case involving former Director

Corporate funding linked to EU patient & consumer groups policy


EMA reviews transparency criteria

HAI research on financial disclosure featured in article: European politicians' call for greater transparency

ACTA, Democracy & Access to Medicines

HAI Europe Statement: EMA talks the ‘conflicts of interest’ talk, but will it walk the walk?

Dutch Minister of Health supports HAI E's financial transparency recommendations to EMA

In perspective: EMA comments on HAI Europe's survey of financial disclosure

Impact of HAI Europe survey results: Two weeks on

HAI Europe survey reveals new data on financial transparency of patient and consumer organisations

HAI Europe recommendations for improved conflict of interest declarations at EMA

ISDB & MiEF criticize EMA over conflict of interest procedures

Review of conflict of interest policies in three European medicines regulation agencies

EU Ombudsman: Transparency rules apply to all documents held by EMA

Patient groups not only for sick people's interests – says Portuguese sociologist

Citizens call for inquiry into EU response to H1N1 outbreak

European Medicines Agency faces tough questions about patient groups' transparency

Patient Groups need dose of transparency